KR102420552B1 - 동물 모델에서의 미엘로퍼옥시다제 산화 활성의 pic1 억제 - Google Patents

동물 모델에서의 미엘로퍼옥시다제 산화 활성의 pic1 억제 Download PDF

Info

Publication number
KR102420552B1
KR102420552B1 KR1020207022678A KR20207022678A KR102420552B1 KR 102420552 B1 KR102420552 B1 KR 102420552B1 KR 1020207022678 A KR1020207022678 A KR 1020207022678A KR 20207022678 A KR20207022678 A KR 20207022678A KR 102420552 B1 KR102420552 B1 KR 102420552B1
Authority
KR
South Korea
Prior art keywords
pic1
dpeg24
subject
mpo
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207022678A
Other languages
English (en)
Korean (ko)
Other versions
KR20200138168A (ko
Inventor
닐 케이. 크리슈나
켄지 쿠니언
Original Assignee
레알타 홀딩스, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 레알타 홀딩스, 엘엘씨 filed Critical 레알타 홀딩스, 엘엘씨
Priority to KR1020227023661A priority Critical patent/KR20220104268A/ko
Publication of KR20200138168A publication Critical patent/KR20200138168A/ko
Application granted granted Critical
Publication of KR102420552B1 publication Critical patent/KR102420552B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/02—Oxidoreductases acting on a peroxide as acceptor (1.11) with H2O2 as acceptor, one oxygen atom of which is incorporated into the product (1.11.2)
    • C12Y111/02002—Myeloperoxidase (1.11.2.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Wood Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
KR1020207022678A 2018-01-09 2019-01-08 동물 모델에서의 미엘로퍼옥시다제 산화 활성의 pic1 억제 Active KR102420552B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227023661A KR20220104268A (ko) 2018-01-09 2019-01-08 동물 모델에서의 미엘로퍼옥시다제 산화 활성의 pic1 억제

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862615183P 2018-01-09 2018-01-09
US62/615,183 2018-01-09
US201862681458P 2018-06-06 2018-06-06
US62/681,458 2018-06-06
US201862746649P 2018-10-17 2018-10-17
US62/746,649 2018-10-17
PCT/US2019/012659 WO2019139886A1 (en) 2018-01-09 2019-01-08 Pic1 inhibition of myeloperoxidase oxidative activity in an animal model

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227023661A Division KR20220104268A (ko) 2018-01-09 2019-01-08 동물 모델에서의 미엘로퍼옥시다제 산화 활성의 pic1 억제

Publications (2)

Publication Number Publication Date
KR20200138168A KR20200138168A (ko) 2020-12-09
KR102420552B1 true KR102420552B1 (ko) 2022-07-13

Family

ID=67140101

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227023661A Ceased KR20220104268A (ko) 2018-01-09 2019-01-08 동물 모델에서의 미엘로퍼옥시다제 산화 활성의 pic1 억제
KR1020207022678A Active KR102420552B1 (ko) 2018-01-09 2019-01-08 동물 모델에서의 미엘로퍼옥시다제 산화 활성의 pic1 억제

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020227023661A Ceased KR20220104268A (ko) 2018-01-09 2019-01-08 동물 모델에서의 미엘로퍼옥시다제 산화 활성의 pic1 억제

Country Status (12)

Country Link
US (5) US11135272B2 (enExample)
EP (2) EP4464716A3 (enExample)
JP (2) JP7031011B2 (enExample)
KR (2) KR20220104268A (enExample)
CN (1) CN112512548A (enExample)
AU (2) AU2019207508B2 (enExample)
CA (1) CA3086407A1 (enExample)
ES (1) ES2996888T3 (enExample)
IL (2) IL287308B2 (enExample)
MX (3) MX2020007098A (enExample)
SG (1) SG11202006063RA (enExample)
WO (1) WO2019139886A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10947279B2 (en) 2015-06-26 2021-03-16 Realta Holdings, Llc Synthetic peptide compounds and methods of use
CA3086407A1 (en) 2018-01-09 2019-07-18 Realta Holdings, Llc Pic1 inhibition of myeloperoxidase oxidative activity in an animal model
BR112023005783A2 (pt) * 2020-09-30 2023-04-25 Realta Life Sciences Inc Peptídeos e métodos de uso
CN116437939A (zh) * 2020-11-02 2023-07-14 瑞尔塔生命科学公司 肽及其使用方法
US20230272012A1 (en) * 2020-11-02 2023-08-31 Realta Life Sciences, Inc. Peptides and methods of use
EP4240392A4 (en) * 2020-11-09 2024-10-09 Realta Life Sciences, Inc. PEPTIDE FORMULATIONS AND METHODS OF USE
IL308683A (en) * 2021-06-01 2024-01-01 Realta Life Sciences Inc Peptides and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160376322A1 (en) * 2010-07-21 2016-12-29 Eastern Virginia Medical School Derivative Peptide Compounds and Methods of Use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625049A (en) 1993-05-12 1997-04-29 Us Health Nucleic acids encoding human astrovirus serotype 2
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
AU3066699A (en) 1998-03-03 1999-09-20 Johns Hopkins University, The Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
AU2729400A (en) 1999-01-19 2000-08-07 James Daly Application of a viral complement inhibitory protein in the treatment and diagnosis of alzheimer's disease
US6696562B1 (en) 2000-07-10 2004-02-24 The United States Of America As Represented By The Secretary Of Agriculture Avian astrovirus
US7638481B2 (en) 2003-09-05 2009-12-29 University Of Louisville Research Foundation, Inc. Treatment of spinal cord injury
DE602004021946D1 (de) 2003-09-05 2009-08-20 Tonen Sekiyukagaku Kk Verfahren zur herstellung einer mikroporösen folie aus thermoplastischem harz
WO2005023296A1 (en) 2003-09-05 2005-03-17 University Of Louisville Research Foundation, Inc. Treatment of rheumatic diseases
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
US7381524B2 (en) 2003-10-10 2008-06-03 Wisconsin Alumni Research Foundation Method to detect antibodies specific for type-2 turkey astrovirus
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
JP5238695B2 (ja) 2006-06-15 2013-07-17 イースタン バージニア メディカル スクール アストロウイルスコートタンパク質およびその誘導体を使用して補体カスケードタンパク質を調節するための方法
EP2069399A2 (en) 2007-04-11 2009-06-17 Pestka Biomedical Laboratories, Inc. Interferons of rhesus and cynomolgus origin and uses thereof
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
WO2011131772A1 (en) 2010-04-22 2011-10-27 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations
ES2626182T3 (es) 2010-07-21 2017-07-24 Eastern Virginia Medical School Compuestos peptídicos para regular el sistema del complemento
CA2867593A1 (en) 2012-03-16 2013-09-19 Belrose Pharma, Inc. Polymeric conjugates of c-1 inhibitors
JP6820917B2 (ja) * 2015-06-26 2021-01-27 レアルタ ホールディングス リミテッド ライアビリティ カンパニー 合成ペプチド化合物及び使用方法
CA3086407A1 (en) 2018-01-09 2019-07-18 Realta Holdings, Llc Pic1 inhibition of myeloperoxidase oxidative activity in an animal model

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160376322A1 (en) * 2010-07-21 2016-12-29 Eastern Virginia Medical School Derivative Peptide Compounds and Methods of Use

Also Published As

Publication number Publication date
JP7341268B2 (ja) 2023-09-08
MX2025009081A (es) 2025-09-02
JP2022068323A (ja) 2022-05-09
US12257290B2 (en) 2025-03-25
SG11202006063RA (en) 2020-07-29
IL275867A (en) 2020-08-31
MX2020007098A (es) 2020-11-11
EP4464716A2 (en) 2024-11-20
US20210252113A1 (en) 2021-08-19
IL287308B2 (en) 2024-03-01
US11135272B2 (en) 2021-10-05
EP3740074B1 (en) 2024-11-06
US20190209660A1 (en) 2019-07-11
IL287308B1 (en) 2023-11-01
US20200230212A1 (en) 2020-07-23
IL287308A (en) 2021-12-01
KR20200138168A (ko) 2020-12-09
CA3086407A1 (en) 2019-07-18
WO2019139886A1 (en) 2019-07-18
EP4464716A3 (en) 2025-02-19
JP7031011B2 (ja) 2022-03-07
KR20220104268A (ko) 2022-07-26
JP2021509916A (ja) 2021-04-08
AU2024205230A1 (en) 2024-09-05
US20230321201A1 (en) 2023-10-12
ES2996888T3 (en) 2025-02-13
US11020460B2 (en) 2021-06-01
IL275867B (en) 2022-01-01
EP3740074A1 (en) 2020-11-25
US20250177492A1 (en) 2025-06-05
EP3740074A4 (en) 2021-10-13
CN112512548A (zh) 2021-03-16
AU2019207508B2 (en) 2024-05-02
MX2025009095A (es) 2025-11-03
AU2019207508A1 (en) 2020-07-09
US11712462B2 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
KR102420552B1 (ko) 동물 모델에서의 미엘로퍼옥시다제 산화 활성의 pic1 억제
Heinen et al. Monitoring and modeling treatment of atypical hemolytic uremic syndrome
JP2018524402A (ja) 合成ペプチド化合物及び使用方法
Chen et al. Properdin is a key player in lysis of red blood cells and complement activation on endothelial cells in hemolytic anemias caused by complement dysregulation
Chen et al. The functional activities of complement factor H are impaired in patients with ANCA-positive vasculitis
Stenson et al. The complement system in pediatric acute kidney injury
US20220096592A1 (en) Pic1 variants with improved solubility and methods of using the same
Smith-Jackson et al. The membrane attack complex drives thrombotic microangiopathy in complement mediated atypical hemolytic uremic syndrome
US20220175886A1 (en) Net stabilization as a therapy for sepsis
Krishna et al. The EPICC family of anti-inflammatory peptides: next generation peptides, additional mechanisms of action, and in vivo and ex vivo efficacy
ES2883952T3 (es) Clusterina para su uso en el tratamiento de microangiopatías trombóticas
Butler et al. Sepsis and septic shock: a review of definitions, pathogenesis, and treatment
Tofferi et al. C3b‐Independent Complement Activation in Ischemia/Reperfusion Mesenteric Tissue Injury in Autoimmune Prone (B6. MRL/lpr) Mice

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200805

Patent event code: PA01051R01D

Comment text: International Patent Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20201111

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210401

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20210401

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210531

Patent event code: PE09021S01D

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211029

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220202

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20211029

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20210531

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220202

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210618

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20210401

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20220408

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20220307

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220202

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20210618

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210401

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220708

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220708

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220711

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250624

Start annual number: 4

End annual number: 4